DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System regulatory update

Elixir received CE Mark approval for its DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System to treat coronary artery disease (CAD). Elixir plans to launch the product later this year. Th...